Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.39 USD | -4.09% | +6.94% | -22.45% |
May. 09 | Transcript : FIGS, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (FIGS) FIGS Reports Q1 Revenue $119.3M, vs. Street Est of $117.4M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 93.74 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.45% | 918M | C- | ||
+9.48% | 27.43B | B+ | ||
-28.65% | 3.18B | B- | ||
-16.08% | 2.53B | C+ | ||
+19.05% | 2.49B | - | A- | |
+11.11% | 2.16B | B | ||
-4.24% | 2.03B | - | ||
+5.56% | 1.61B | B | ||
+1.69% | 1.31B | - | ||
+29.73% | 1.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FIGS Stock
- Ratings FIGS, Inc.